Targeting the intestinal L-cell for obesity and type 2 diabetes treatment

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Targeting the intestinal L-cell for obesity and type 2 diabetes treatment. / Albrechtsen, Nicolai Jacob Wewer; Kuhre, Rune Ehrenreich; Deacon, Carolyn F.; Holst, Jens Juul.

In: Expert Review of Endocrinology & Metabolism, Vol. 9, No. 1, 01.01.2014, p. 61-72.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Albrechtsen, NJW, Kuhre, RE, Deacon, CF & Holst, JJ 2014, 'Targeting the intestinal L-cell for obesity and type 2 diabetes treatment', Expert Review of Endocrinology & Metabolism, vol. 9, no. 1, pp. 61-72. https://doi.org/10.1586/17446651.2014.862152

APA

Albrechtsen, N. J. W., Kuhre, R. E., Deacon, C. F., & Holst, J. J. (2014). Targeting the intestinal L-cell for obesity and type 2 diabetes treatment. Expert Review of Endocrinology & Metabolism, 9(1), 61-72. https://doi.org/10.1586/17446651.2014.862152

Vancouver

Albrechtsen NJW, Kuhre RE, Deacon CF, Holst JJ. Targeting the intestinal L-cell for obesity and type 2 diabetes treatment. Expert Review of Endocrinology & Metabolism. 2014 Jan 1;9(1):61-72. https://doi.org/10.1586/17446651.2014.862152

Author

Albrechtsen, Nicolai Jacob Wewer ; Kuhre, Rune Ehrenreich ; Deacon, Carolyn F. ; Holst, Jens Juul. / Targeting the intestinal L-cell for obesity and type 2 diabetes treatment. In: Expert Review of Endocrinology & Metabolism. 2014 ; Vol. 9, No. 1. pp. 61-72.

Bibtex

@article{bab9123d330b45b4a84300aeb29e8c17,
title = "Targeting the intestinal L-cell for obesity and type 2 diabetes treatment",
abstract = "Degradation-resistant glucagon-like peptide-1 (GLP-1) mimetics and GLP-1 enhancers (inhibitors of dipeptidyl peptidase-4, the enzyme which degrades and inactivates GLP-1) have been used for treatment of type 2 diabetes mellitus since 2005-2006. Cutting-edge research is now focusing on uncovering the secretory mechanisms of the GLP-1-producing cells (L-cells) with the purpose of developing agonists that enhance endogenous hormone secretion. Since GLP-1 co-localizes with other anorectic peptides, cholecystokinin, oxyntomodulin/glicentin and peptide YY, L-cell targeting might cause release of several hormones at the same time, providing additive effects on appetite and glucose regulation. In this review, we explore the role of proglucagon-derived peptides and other L-cell co-localizing hormones, in appetite regulation and the mechanism regulating their secretion.",
keywords = "appetite regulation, gut hormones, gut-brain axis, L-cell, obesity",
author = "Albrechtsen, {Nicolai Jacob Wewer} and Kuhre, {Rune Ehrenreich} and Deacon, {Carolyn F.} and Holst, {Jens Juul}",
year = "2014",
month = "1",
day = "1",
doi = "10.1586/17446651.2014.862152",
language = "English",
volume = "9",
pages = "61--72",
journal = "Expert Review of Endocrinology & Metabolism",
issn = "1744-6651",
publisher = "Taylor & Francis",
number = "1",

}

RIS

TY - JOUR

T1 - Targeting the intestinal L-cell for obesity and type 2 diabetes treatment

AU - Albrechtsen, Nicolai Jacob Wewer

AU - Kuhre, Rune Ehrenreich

AU - Deacon, Carolyn F.

AU - Holst, Jens Juul

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Degradation-resistant glucagon-like peptide-1 (GLP-1) mimetics and GLP-1 enhancers (inhibitors of dipeptidyl peptidase-4, the enzyme which degrades and inactivates GLP-1) have been used for treatment of type 2 diabetes mellitus since 2005-2006. Cutting-edge research is now focusing on uncovering the secretory mechanisms of the GLP-1-producing cells (L-cells) with the purpose of developing agonists that enhance endogenous hormone secretion. Since GLP-1 co-localizes with other anorectic peptides, cholecystokinin, oxyntomodulin/glicentin and peptide YY, L-cell targeting might cause release of several hormones at the same time, providing additive effects on appetite and glucose regulation. In this review, we explore the role of proglucagon-derived peptides and other L-cell co-localizing hormones, in appetite regulation and the mechanism regulating their secretion.

AB - Degradation-resistant glucagon-like peptide-1 (GLP-1) mimetics and GLP-1 enhancers (inhibitors of dipeptidyl peptidase-4, the enzyme which degrades and inactivates GLP-1) have been used for treatment of type 2 diabetes mellitus since 2005-2006. Cutting-edge research is now focusing on uncovering the secretory mechanisms of the GLP-1-producing cells (L-cells) with the purpose of developing agonists that enhance endogenous hormone secretion. Since GLP-1 co-localizes with other anorectic peptides, cholecystokinin, oxyntomodulin/glicentin and peptide YY, L-cell targeting might cause release of several hormones at the same time, providing additive effects on appetite and glucose regulation. In this review, we explore the role of proglucagon-derived peptides and other L-cell co-localizing hormones, in appetite regulation and the mechanism regulating their secretion.

KW - appetite regulation

KW - gut hormones

KW - gut-brain axis

KW - L-cell

KW - obesity

U2 - 10.1586/17446651.2014.862152

DO - 10.1586/17446651.2014.862152

M3 - Journal article

AN - SCOPUS:84893138518

VL - 9

SP - 61

EP - 72

JO - Expert Review of Endocrinology & Metabolism

JF - Expert Review of Endocrinology & Metabolism

SN - 1744-6651

IS - 1

ER -

ID: 129244994